parkinson's disease triple agonist glp-1 gip glucagon clinical trial Science Behind GLP 1 and Receptor Agonists for Obesity Research | News & Announcements Incretin Hormones GLP-1 and GIP

GLP-1R biased cAMP agonism maintains glycemic control with reduced malaise and emesis in preclinical mammalian models Glucagon-like peptide-1 receptor (GLP-1R) agonists improve glycemic control and promote weight loss in diabetes and obesity but are also associated with gastrointestinal adverse events, including nausea and emesis in many patients

Anticholinergic drugs include antihistamines (such as Benadryl), tricyclic antidepressants, and medicines for overactive bladder and Parkinson's disease

Van Cauter E, Leproult R, Plat L

According to the message boards I viewed, those trying to build muscle or lose weight often take carnitine before a workout to maximize how their bodies burn fat